Fatty liver diseases, bile acids, and FXR

Yan Zhu, Hongxia Liu, Min Zhang, Grace L. Guo

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

The prevalence of nonalcoholic fatty liver disease (NAFLD) worldwide has increased at an alarming rate, which will likely result in enormous medical and economic burden. NAFLD presents as a spectrum of liver diseases ranging from simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and even to hepatocellular carcinoma (HCC). A comprehensive understanding of the mechanism(s) of NAFLD-to-NASH transition remains elusive with various genetic and environmental susceptibility factors possibly involved. An understanding of the mechanism may provide novel strategies in the prevention and treatment to NASH. Abnormal regulation of bile acid homeostasis emerges as an important mechanism to liver injury. The bile acid homeostasis is critically regulated by the farnesoid X receptor (FXR) that is activated by bile acids. FXR has been known to exert tissue-specific effects in regulating bile acid synthesis and transport. Current investigations demonstrate FXR also plays a principle role in regulating lipid metabolism and suppressing inflammation in the liver. Therefore, the future determination of the molecular mechanism by which FXR protects the liver from developing NAFLD may shed light to the prevention and treatment of NAFLD.

Original languageEnglish (US)
Pages (from-to)409-412
Number of pages4
JournalActa Pharmaceutica Sinica B
Volume6
Issue number5
DOIs
StatePublished - Sep 1 2016

Fingerprint

Fatty Liver
Bile Acids and Salts
Liver Diseases
Homeostasis
Fibrosis
Medical Economics
Non-alcoholic Fatty Liver Disease
Liver
Genetic Predisposition to Disease
Lipid Metabolism
Hepatocellular Carcinoma
Inflammation
Wounds and Injuries

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics(all)

Keywords

  • Bile acids
  • Farnesoid X receptor
  • Liver lipid metabolism
  • Nonalcoholic fatty liver disease
  • Nonalcoholic steatohepatitis

Cite this

Zhu, Yan ; Liu, Hongxia ; Zhang, Min ; Guo, Grace L. / Fatty liver diseases, bile acids, and FXR. In: Acta Pharmaceutica Sinica B. 2016 ; Vol. 6, No. 5. pp. 409-412.
@article{17fa2a9b48dc4f078f8e47b4c0fd333e,
title = "Fatty liver diseases, bile acids, and FXR",
abstract = "The prevalence of nonalcoholic fatty liver disease (NAFLD) worldwide has increased at an alarming rate, which will likely result in enormous medical and economic burden. NAFLD presents as a spectrum of liver diseases ranging from simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and even to hepatocellular carcinoma (HCC). A comprehensive understanding of the mechanism(s) of NAFLD-to-NASH transition remains elusive with various genetic and environmental susceptibility factors possibly involved. An understanding of the mechanism may provide novel strategies in the prevention and treatment to NASH. Abnormal regulation of bile acid homeostasis emerges as an important mechanism to liver injury. The bile acid homeostasis is critically regulated by the farnesoid X receptor (FXR) that is activated by bile acids. FXR has been known to exert tissue-specific effects in regulating bile acid synthesis and transport. Current investigations demonstrate FXR also plays a principle role in regulating lipid metabolism and suppressing inflammation in the liver. Therefore, the future determination of the molecular mechanism by which FXR protects the liver from developing NAFLD may shed light to the prevention and treatment of NAFLD.",
keywords = "Bile acids, Farnesoid X receptor, Liver lipid metabolism, Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis",
author = "Yan Zhu and Hongxia Liu and Min Zhang and Guo, {Grace L.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.apsb.2016.07.008",
language = "English (US)",
volume = "6",
pages = "409--412",
journal = "Acta Pharmaceutica Sinica B",
issn = "2211-3835",
publisher = "Elsevier BV",
number = "5",

}

Fatty liver diseases, bile acids, and FXR. / Zhu, Yan; Liu, Hongxia; Zhang, Min; Guo, Grace L.

In: Acta Pharmaceutica Sinica B, Vol. 6, No. 5, 01.09.2016, p. 409-412.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Fatty liver diseases, bile acids, and FXR

AU - Zhu, Yan

AU - Liu, Hongxia

AU - Zhang, Min

AU - Guo, Grace L.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - The prevalence of nonalcoholic fatty liver disease (NAFLD) worldwide has increased at an alarming rate, which will likely result in enormous medical and economic burden. NAFLD presents as a spectrum of liver diseases ranging from simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and even to hepatocellular carcinoma (HCC). A comprehensive understanding of the mechanism(s) of NAFLD-to-NASH transition remains elusive with various genetic and environmental susceptibility factors possibly involved. An understanding of the mechanism may provide novel strategies in the prevention and treatment to NASH. Abnormal regulation of bile acid homeostasis emerges as an important mechanism to liver injury. The bile acid homeostasis is critically regulated by the farnesoid X receptor (FXR) that is activated by bile acids. FXR has been known to exert tissue-specific effects in regulating bile acid synthesis and transport. Current investigations demonstrate FXR also plays a principle role in regulating lipid metabolism and suppressing inflammation in the liver. Therefore, the future determination of the molecular mechanism by which FXR protects the liver from developing NAFLD may shed light to the prevention and treatment of NAFLD.

AB - The prevalence of nonalcoholic fatty liver disease (NAFLD) worldwide has increased at an alarming rate, which will likely result in enormous medical and economic burden. NAFLD presents as a spectrum of liver diseases ranging from simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and even to hepatocellular carcinoma (HCC). A comprehensive understanding of the mechanism(s) of NAFLD-to-NASH transition remains elusive with various genetic and environmental susceptibility factors possibly involved. An understanding of the mechanism may provide novel strategies in the prevention and treatment to NASH. Abnormal regulation of bile acid homeostasis emerges as an important mechanism to liver injury. The bile acid homeostasis is critically regulated by the farnesoid X receptor (FXR) that is activated by bile acids. FXR has been known to exert tissue-specific effects in regulating bile acid synthesis and transport. Current investigations demonstrate FXR also plays a principle role in regulating lipid metabolism and suppressing inflammation in the liver. Therefore, the future determination of the molecular mechanism by which FXR protects the liver from developing NAFLD may shed light to the prevention and treatment of NAFLD.

KW - Bile acids

KW - Farnesoid X receptor

KW - Liver lipid metabolism

KW - Nonalcoholic fatty liver disease

KW - Nonalcoholic steatohepatitis

UR - http://www.scopus.com/inward/record.url?scp=84995478579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995478579&partnerID=8YFLogxK

U2 - 10.1016/j.apsb.2016.07.008

DO - 10.1016/j.apsb.2016.07.008

M3 - Review article

AN - SCOPUS:84995478579

VL - 6

SP - 409

EP - 412

JO - Acta Pharmaceutica Sinica B

JF - Acta Pharmaceutica Sinica B

SN - 2211-3835

IS - 5

ER -